The oral mucosa represents the first part of the digestive tract and is exposed to various exogenous toxins. Exposure for longer duration can lead to changes that lead to potentially malignant diseases or cancers / Tumors. Eventually these can be diagnosed by routine histopathology, but few of them are difficult to diagnose by this method alone. There arises the role of tumor markers in distinguishing different pathologies is well established. A marker can be described as some inconspicuous object used to distinguish or mark certain things. Mostly tumor markers are proteins and these markers may be detected within exfoliated or distributed cells, or as circulating agents within the peripheral blood or plasma. In the recent years, there is a renewed interest about tumor markers, providing window of opportunity for management of cancer patients by enhancing the efficiency in detection and treatment plan. Recent technological advancement has enabled the examination of many potential markers. This paper focuses on the tumor markers in the head and neck neoplasm.
INTRODUCTION
Oral cancer, mainly represented by oral squamous cell carcinoma (OSCC), is the eighth most common cancer worldwide accounting for more than 300,000 new cases and 145,000 deaths in 2012. Usually detection of oral cancer depends on the clinical examination of the oral cavity followed by biopsy for histopathological conformation. OSCC is most often identified in the advanced stages of the disease, which may be a reason for reduced survival rate of cancer patients. Even though we are advancing in treatment modalities, less than 50% of OSCC patients have reduced survival rate. Tumor markers play an important role in screening high risk cancer patient and they can predict the prognosis of the disease.
Tumor markers are substances produced by tumor cells or by other cells within the body in response to cancer or certain benign conditions. It includes a variety of substances like cell surface antigens, cytoplasmic proteins, enzymes, hormones, oncofetal antigens, receptors, oncogens and their products [1] [2] [3] . There are different tumor markers, some of which are seen in specific tumors known as Tumor specific markers, while many markers can be found in various other tumors known as Tumor associated markers [1, 4] .
Although an abnormal level of these markers may suggest tumorigenic pathology, but their presence does not confirm it. Other uses of tumor markers, is to assess a cancer response to treatment and to check for its recurrence. In some types of cancers, tumor marker levels may reflect the presence of the disease but are not predictive of the stage of the disease.
Tumor markers present in circulating body fluids and in the tissue. In the circulating body fluids we can see VEGF/VEGF-R (Vascular endothelial growth factor/receptor) PD-ECGF (Plateletderived endothelial cell growth factor) FGFs (Fibroblast growth factor), BCL2, Cathepsin -D, CD44, CD80, CD105, Endoglin, Cytokeritins, CEA, CA-19-9, CA-125, SCC-Ag, calretinin, Cerb2, Cyclin, MIB and p 53 [4, 5] . [6] .
The concept of Ideal Tumor Markers (Theoretically) [7, 8] 1) They should be highly sensitive and should have low false negative. 2) They should be highly specific and should have low false positive. 3) They should have high positive and negative predictive value. 4) It should be accurate in differentiating between healthy individuals and tumor patients. 5) They should be able to differentiate between neoplastic and non-neoplastic disease and show positive correlation with tumor volume and extent. 6) They should predict early recurrence and have prognostic value. 7) Their levels should be preceding the neoplastic process, so that it should be useful for screening early cancer. 8) They should be either a universal markers for all types of malignancies or specific to one type of malignancy. 9) Be easily assayable and able to indicate all changes in cancer patients receiving treatment.
But unfortunately none of the tumor markers reported till date have above ideal characteristics.
CLASSIFICATION [7]
According to Schliephake Clinical staging of cancer is aided by quantization of the marker; i.e. serum level of marker reflects the burden of the tumor.
• Screening in general population Clinical & histological features alone cannot accurately predict whether potentially malignant disorders will remain stable, regress or progress to malignancy. Some of them with or without epithelial dysplasia may transform to invasive oral SCC. Hence identification of T.M which can predict disease progression is necessary to improve the management of these lesions [4, 6] .
TGF alpha, EGFR and FGF2 help in normal growth and differentiation of oral keratinocytes. Increased expression of these markers may constitute as useful early marker in head and neck carcinogenesis [8, 12] .
In one study it was that a significant association was found between the decrease of serum EGFR and the absence of distant metastasis in HNC. The most interesting result was that combining sEGFR and EGF, 100% in HNC were reached without losing specificity (97.8% in both cases). These data demonstrate a potentially interesting value of the serum levels of sEGFR and EGF, especially when combined, as markers for HNC [10] .
Srinivasan M and Jewel SD observed the elevated expression of TGF & EGFR in premalignant lesions with dysplasia, as intermediate marker of malignancy. Quantitative measurement of these proteins may provide intermediate endpoints in prospective chemopreventive trials [12] . Kang et al. [13] showed an enhanced Bmi (B lymphoma Mo-MLV insertion region 1 homolog) (an oncogene) expression in pre malignant lesion and cancerous condition, they may act through p16INK4A-independent pathways to regulate cellular proliferation during oral carcinogenesis. Survivin, an apoptotic inhibitor might act as a prognostic marker, which is unregulated when the premalignant lesions are transforming to oral cancer. Survivin was present in 10/30 cases (33%) of oral precancerous lesions, and in 15/16 cases (94%) of oral precancerous lesions evolved into full-blown squamous cell carcinoma. [13] P 53 is a tumor suppressor gene which plays an important role in normal regulation of cellular growth and proliferation. P 53 alterations were noted about 10-50 % in potentially malignant diseases. Mutations in this gene are mostly reported in oral cancer with reported prevalence of 30 -60%. [14] In recent literature it is revealed that mutant p53 is not just one protein, but a multitude of proteins that can contribute to a wide range of oncogenic processes. Designing drug strategies to target mutant p53 tumors is therefore highly challenging [15] . lymphoma 2) , is the regulator protein that regulates cell death (apoptosis). The aberrant bcl-2 expression and loss of p53 function was observed, which may play an important role in the tumorigenesis of oral cancers by allowing escape from apoptosis and enabling additional genetic alterations to accrue. [13] Bcl-2 has been suggested, as a significant prognostic indicator in early Squamous Cell Carcinoma of head and neck. The predictive role in immune-histochemical detection of the Sphase cell fraction were investigated within a prospective randomized phase III clinical trial on squamous cell carcinomas (SCC) of the oral cavity, including surgery or primary chemotherapy [16] .
BCL-2 (B-cell
Beta 2-Microglobulin: also known as B2M is a component of MHC class I molecules, which are present on all nucleated cells. A definite increase in the level of beta 2-microglobulin was observed in patients with leukoplakia, oral submucous fibrosis and oral cancer [17, 18] .
Cathepsin-D(CD):
A protease, which is an invasion promoter and plays a central role in oral cancer, is postulated to promote tumor invasion and metastasis. It is a potential independent predictor of cervical lymph node metastasis in Head and Neck SCC [19] . In one study they have concluded that CD expression can be used for the assessment of patient survival in cases of OSCC [20] .
CD44, CD80, CD105 (ENDOGLIN):
In oral SCC's, expression of CD80 may serve as a marker for increased tumourogenicity, during early development and expression of CD44 correlated with decreased survival rate [1, 8, 17] .
Cytokeratins: Cytokeratins (CK) and vimentin are epithelia and mesenchymal predominant intermediate filament proteins respectively. Monospecific keratin antibodies are useful for evaluation of epithelial differentiation, changes in oral dysplasias and oral SCC. Simple epithelial keratins (K8, K18, K19) may be relevant to tumor prognosis. CK19 and CK8 are markers of premalignant lesions, which are changing to head and neck cancer [1, 5, 8] . Serum-soluble fragments of cytokeratin 19 can be measured in terms of CYFRA (cytokeratin-19 fragment) levels, this marker has shown 95% specificity and 60% sensitivity for head and neck squamous cell carcinoma at a cut-off value of 2.2 ng/mL, significantly lower CYFRA levels were detected in both smaller and earlier-staged tumors [21] .
CEA, CA19-9, CA125, SCC-Ag: Examination of tumor markers in the saliva of OSCC patients showed significant increase in Cyfra 21-1 a tissue polypeptide antigen, and CA125. Salivary concentrations of CA19-9, SCC-Ag, and carcinoembryonic antigen were also increased with no statistical significance [22] [23] [24] .
C-erb2
(v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2) the aberrations of erbB-1 and erbB-2 are additional markers in premalignant oral lesions at the beginning of the carcinogenic process. Expression of C-erbB-2 was also associated with significantly high risk of recurrence of tongue SCC [8] .
Cyclin, MIB:
Cyclins functions as regulators of CDK kinase. Different cyclins exhibit distinct expression of each mitotic event. This cyclin forms a complex and functions as a regulatory subunit of CDK4 or CDK6, whose activity is, required for cell cycle G1/S transition. This protein has been shown to interact with tumour suppressor protein Rb and the expression of this gene is regulated positively by Rb. Mutations, amplification and overexpression of this gene, alters cell cycle progression observed frequently in a variety of tumours and may contribute to tumorigenesis. Proliferative markers like cyclins and MIB in the basal and superficial cells of premalignant lesions may serve as surrogate end point biomarkers for chemoprevention trials. Cyclin D1, Ki6758, CKD259 over expression were positively correlated in OSCC and Cyclin A activity predicts, clinical outcome in oral precancer and cancer [5, 8, 25, 26] .
Growth factors:
Growth factors typically act as signaling molecules between cells. They can promote (EGF, PDGF, NGF) / inhibit (TGF) the growth of cells. VEGF may be an important angiogenic factor associated with cancer cells in SCCHN [27] [28] [29] . A literature review of potential molecular markers relevant to SCCHN in the early part of this decade suggested EGFR, TGF-α, Cyclin D1 and p53 as emerging molecular markers that might provide independent prognostic information [1] .
EGFR signalling regulates β-catenin localization and stability, target gene expression. Moreover, it was suggested that aberrant accumulation of β-catenin under EGFR activation, is a malignancy marker of oral cancer. In one study it was demonstrated that in addition to mutation of APC and β-catenin, oncogenic changes like downstream of EGFR, play important roles in regulating the nuclear translocation of β-catenin, a process that remodels histone/chromatin binding regions in target genes, and ultimately leads to the progression of oral cancer [30] .
p53: (also known as protein 53 or tumor protein 53), is a tumor suppressor protein that in humans is encoded by the TP53 gene. p53 expression may be a valuable marker for identifying individuals at high risk of developing a recurrence of primary disease and second primary tumors of SCCHN [28, 31, 32] (Table 1) .
Even Serum β2-microglobulin, Total Sialic Acid (TSA), Lipid-Bound Sialic Acid (LSAB) and elevated salivary defensin-1 were found to be indicative for malignant changes [33, 34] .
CLINICAL APPLICATIONS OF TUMOR MARKERS
Ideally, a tumor marker should be produced by the tumor cells and be detectable in body fluids. It should not be present in healthy people or in benign conditions. Therefore, it could be used for screening for the presence of cancer in asymptomatic individuals in a general population. However certain tumor markers may be detected in normal individuals also, for example the values in smokers for CEA is higher than normal individuals but, the pattern of change is indicative of pathology, yet the smokers CEA is still lower than certain level, comparative to a malignancy (Table 2 ) [1, 8, 16] .
Clinical utility depends on the specificity, sensitivity, positive predictive accuracy and negative predictive accuracy of the tumor marker [5, 7, 28] . Role of tumor markers in oral squamous cell carcinoma were mentioned in Table 3 .
The salivary biomarkers which are significantly altered in OSCC patients are inhibitors of apoptosis (IAP), squamous cell carcinoma associated antigen (SCC-Ag), carcinoembryonic antigen (CEA), carcino-antigen (CA19-9) , CA128, serum tumor marker (CA125), intermediate filament protein (Cyfra 21-1) , tissue polypeptide specific antigen (TPS), reactive nitrogen species (RNS) and 8-OHdG DNA damage marker, lactate dehydrogenase (LDH) and immunoglobulin (IgG), s-IgA , insulin growth factor (IGF), metalloproteinases MMP-2 and MMP-11 [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] .
Altered expression of miRNA is a common finding in OSCC tumorigenesis. Molecular regulators like miRNAs, 18-25 nucleotides long, noncoding RNA molecules, have recently gained significant attention as potential regulators and biomarkers for human carcinogenesis. Deregulated expression of miRNAs in OSCC when compared to their normal counterparts, indicating their potential role in oral cancer development [14, 47] .
In the literature it was observed that OSCC showed significantly downregulated expression of miR-26a and miR-26b in OSCC tissues, suggesting that miR-26a and miR-26b may act as tumour suppressors [48] . 
CONCLUSION
Tumor markers play an important role in screening high risk population for the presence of neoplasm, these markers help in making diagnosis they also determine the prognosis of the lesion in the patient, during the treatment course or at remission period. Every year clinicians are discovering new tumor markers. Despite the specificity of some tumor markers, a negative marker value does not rule out recurrent disease and other diagnostic modalities have to be performed. To identify minor quantity of substances in serum, currently there are no test for tumor marker of adequate sensitivity and specificity for early diagnosis.
Even though we are advancing in the field of medicine but still certain amount of confusion exists about the value of tumour markers in a patient with cancer. Intuitively, a panel of tumour markers should help to establish the origin of the tumour. Unfortunately, most tumour markers are too nonspecific for this purpose.
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